We feel that this new initiative will give sponsor companies access to the right experts very early in the process and will help us increase our ability to keep our Troika Promise to every client of speed, quality and cost.
MOSCOW, Russia (PRWEB) January 28, 2015
Synergy Research Group is addressing one of the most common roadblocks to clinical trial ramp-up by taking sales and business development out of the proposal and/or bid cycle. This is another step in Synergy’s commitment to offer quality, speed and lower cost to every sponsor.
Every prospective client or new project will be assigned an experienced study manager from the outset. The manager will bring in a team of experts on regulatory affairs, medical writing and others as needed to ensure that the full scope of the project is taken into consideration at the earliest possible moment, before a bid or proposal is submitted. Under this structure, the trial will be operational as soon as the sponsor approves the project.
“I’ve talked to a number of colleagues in the CRO industry and the delay that occurs during the handoff from business development to the beginning of the trial is a common concern,” said Igor Stefanov, CEO of Synergy Research Group. “By eliminating sales and business development and having the study manager involved from the outset will eliminate the ramp-up time and save sponsors time and administrative costs.”
The company has implemented a number of initiatives designed to increase transparency and offer the highest quality to sponsor companies. These initiatives include an interactive dashboard that gives a snapshot of the progress and health of all of the projects that Synergy is currently involved in. The company is known for its Orange Papers, that deliver analysis of the state of clinical trials in the region.
“We feel that this new initiative will give sponsor companies access to the right experts very early in the process and will help us increase our ability to keep our Troika Promise to every client of speed, quality and cost,” Stefanov continued. “This restructuring of the business development and ramp-up process is another step in our continuing efforts to provide the best value and quality to our clients.”
Russia boasts large patient populations across high-demand therapeutic areas such as oncology, infectious disease, and cardiovascular. Per-patient study costs are low in the region, despite having a large number of experienced researchers in multiple sites. Additionally, the per-patient spend on pharmaceuticals in the region is expected to more than double by 2016, growing to over four billion dollars annually.
Synergy Research Group leads the Russian market in full-service contract research. The company has senior management teams with deep domain expertise, as well as executives with experience working inside regulatory agencies who speed the approval processes.
About Synergy Research Group
Synergy Research Group, http://synergycro.ru/, is a full-service Contract Research Organization (CRO) founded in 2002 that delivers its Troika Promise of Speed, Cost and Quality to clients. Synergy provides a full range of CRO services to help global pharmaceutical and biotechnology companies conduct successful and cost-effective clinical trials. The company provides transparency, access and control to sponsors during the entire project through its cloud-based monitoring system. Synergy has locations in Moscow, Saint-Petersburg, Novosibirsk, Yekaterinburg, Perm, Krasnodar, Almaty and Astana (Kazakhstan) and Kyiv (Ukraine). The company's headquarters are in Moscow.